SABCS 2025 Top Abstracts | Decera Clinical Education

An Expert’s Guide to SABCS 2025: A Preview of the Top Abstracts

Released: December 08, 2025

Activity

Progress

Course Completed

Continue

During the 2025 San Antonio Breast Cancer Symposium (SABCS), exciting and important results from many studies will be reported. In this conference preview commentary, Sara M. Tolaney, MD, MPH, and Virginia Kaklamani, MD, DSc, highlight some of the abstracts they are looking forward to seeing presented at the meeting, some with the potential to change the current treatment landscape of patients with early or advanced/metastatic breast cancer.

We will cover these abstracts in more detail as part of the Decera Clinical Education Independent Conference Coverage of SABCS 2025. Remember to check the Decera Clinical Education website often as the meeting unfolds to check for downloadable slidesets summarizing the data from these studies and more. After the conference, review the CME-certified expert analysis text module with experts’ perspectives on the current and potential future clinical implications of these new data.

Top Picks
The following abstracts are highly anticipated by the experts:

Early Breast Cancer (EBC)

AXSANA/EUBREAST 3(R): primary endpoint analyses from an international, prospective, multicenter study evaluating more vs less invasive axillary surgical staging procedures in patients with EBC converting from a clinically node-positive to a clinically node-negative stage through neoadjuvant CT (Abstract GS2-01).
Exploratory analysis from ALTTO (BIG 2-06) study of adjuvant aromatase inhibitor (AI) or tamoxifen in patients with hormone receptor (HR)–positive/HER2-positive EBC (Abstract GS1-03).
Primary analysis from phase II SOLTI-2104- PremiÈRe trial: elacestrant with or without triptorelin in premenopausal women with estrogen receptor (ER)–positive/HER2-negative EBC (Abstract PD10-01).
Phase III lidERA: trial exploring neoadjuvant giredestrant compared with standard-of-care endocrine therapy (ET) for patients with ER-positive/HER2- EBC (Abstract GS-10).
TBCRC-053 (P-RAD): primary results from a randomized trial of no, low-, or high-dose preoperative radiation combined with pembrolizumab and CT in the HR-positive/HER2-negative cohort of patients with node-positive breast cancer (Abstract GS2-05).
Subgroup analysis from MonarchE: adjuvant abemaciclib plus ET in HR-positive/HER2-negative high-risk EBC per nodal status (Abstract PS1-08-08).
Phase III NATALEE (5-year analysis): distant disease-free survival results in key subgroups of patients receiving ribociclib plus a nonsteroidal AI and HR-positive/HER2-negative EBC (Abstract PS3-09-08).
DESTINY-Breast11: safety: neoadjuvant T-DXd alone or followed by THP compared with ddAC-THP in patients with high-risk HER2-positive EBC (Abstract RF6-02).

Additional studies of interest in EBC include:
Translational analysis of ctDNA clearance in PHERGain: a tailored treatment study in patients with HER2-positive EBC undergoing neoadjuvant dual HER2 blockade with trastuzumab and pertuzumab (Abstract GS1-06).

Advanced/Metastatic Breast Cancer (MBC)

Phase III Her2climb-05: randomized, double-blind trial evaluating maintenance tucatinib compared with placebo in combination with trastuzumab and pertuzumab in patients with HER2-positive MBC (Abstract GS1-01).
ELEVATE (phase II results): elacestrant combined with everolimus or abemaciclib in patients with ER-positive/HER2-negative locally advanced or MBC (Abstract RF7-01).
Phase III EMBER-3 (updated efficacy): imlunestrant with or without abemaciclib in patients with advanced breast cancer (ABC) (Abstract GS3-08).
Clinical and biomarker subgroup analysis from phase III evERA trial of giredestrant plus everolimus in patients with ER-positive/HER2-negative ABC who previously received a CDK4/6 inhibitor (Abstract GS3-09).
Evaluation of blood- and tissue-based PIK3CA gene alteration detection assays in the phase III INAVO120 trial evaluating palbociclib plus fulvestrant with or without inavolisib for HR-positive/HER2-negative ABC (Abstract PS1-10-26).
PIKALO-1: updated results from a phase I/II trial of LY4064809 (STX-478), a pan mutant–selective PI3Kα inhibitor in patients with HR-positive/HER2-negative ABC (Abstract PS1-08-24).
Phase II DATO-BASE trial (Cohort C): report of intracranial activity with datopotamab deruxtecan in patients with HER2-negative ABC and leptomeningeal disease (Abstract PS1-09-02).
An international multicenter cohort study report of the safety of combining radiotherapy plus sacituzumab govitecan in patients advanced triple-negative breast cancer (TNBC) (Abstract PS1-08-01).
Safety analysis from phase III ASCENT-03 trial of sacituzumab govitecan compared with CT in previously untreated patients with advanced TNBC who are not candidates for anti–PD-(L)1 inhibitors (Abstract PS1-13-24).
Safety analysis from phase III ASCENT-04 trial evaluating sacituzumab govitecan plus pembrolizumab compared with pembrolizumab plus CT in patients with previously untreated PD-L1–positive metastatic TNBC (Abstract PS5-02-28).
Additional safety from phase III TROPION-Breast02 of frontline treatment with datopotamab deruxtecan compared with CT in patients with locally recurrent, inoperable, or metastatic TNBC for whom immunotherapy is not an option (Abstract PS5-03-05).

Additional studies of interest in ABC/MBC include:

ESR1m ctDNA Dynamics and Updated Results from phase III SERENA-6: a study of camizestrant plus CDK4/6 inhibitor in patients with HR-positive/HER2-negative and emergent ESR1 alterations while receiving frontline ET-based treatment prior to disease progression (Abstract RF7-03).
Phase III SERENA-6 study of camizestrant plus CDK4/6 inhibitor in patients with HR-positive/HER2-negative and emergent ESR1 alterations while receiving frontline ET-based treatment prior to disease progression: visual functioning and visual effects (Abstract PD10-04).
Phase III ASCENT-07: primary results from a trial evaluating sacituzumab govitecan compared with CT as frontline therapy after ET in patients with HR-positive/HER2-negative and IHC 0, 1+, or 2+/ISH-negative status and MBC (Abstract GS1-09).
Pooled analyses of long-term progression-free survival from MONALEESA (-2, -3, and -7) studies of all frontline patients with ABC receiving ribociclib plus ET (Abstract PD5-10).
ctDNA analyses from the phase III EMBER-3 clinical trial of imlunestrant with or without abemaciclib in patients with ER-positive/HER2-negative ABC (Abstract PD5-08).

Remember to Check the Decera Clinical Education Website Often During and After SABCS 2025!
Downloadable slideset summaries of many of these key studies will be available on the website as the data are released. After SABCS 2025, register to attend a Best of SABCS live webinar and/or review comprehensive expert analyses CME-certified text-based module and explore the clinical implications of these data.

Continue

Poll

1.

What topic being presented at SABCS 2025 are you most interested in this year?

A. New results on the surgical management of EBC
B. New results with systemic therapy for HER2-positive EBC
C. New results with systemic therapy for HR-positive/HER2-negative EBC
D. New results with systemic therapy for HER2-positive ABC
E. New results with systemic therapy for HR-positive ABC
F. New results with systemic therapy for advanced TNBC
G. Something else (please leave a comment)

Submit

Clinical Education Alliance Terms and Conditions

These Terms of Use ("Terms") apply to your use of the websites, mobile applications and other resources provided by Clinical Education Alliance LLC (“CEA”) and its affiliates (referred to collectively as "CEA," "us," "we" and "our") that are intended for use by healthcare professionals, which we refer to as the "CEA Network," including the personalized information and services that meet the needs and interests of users of the CEA Network such as medical news, reference content, clinical tools, applications, sponsored programs, advertising, email communications, continuing medical education, market research opportunities and discussion forums (collectively, the "Services"). You will always be able to view the most current version of these Terms by clicking on the Terms of Use link at the bottom of any page of a CEA Network property. Note that these Terms do not apply to our properties and services that display a link to different terms of use. In the event that we expand the CEA Network through our acquisition of another company and/or its properties, that company may operate its properties subject to its own terms of use accessible via a link on such properties until we integrate its practices with ours, at which point a link to these Terms will be displayed on its properties. By using the Services, you agree to these Terms, whether or not you are a registered member of the CEA Network. These Terms govern your use of the Services and create a binding legal agreement that we may enforce against you in the event of a violation. If you do not agree to all of these Terms of Use, do not use the Services!

We reserve the right to change these terms from time to time. The most current version may be viewed by clicking on the “Terms of Use” link at the bottom of designated pages on the Clinical Education Alliance Sites. Use of the Clinical Education Alliance Sites after the effective date constitutes acceptance of the amended Terms of Use. When you leave a CEA Web site and go to another Web site, different terms apply and CEA has no responsibility or liability for any content on those sites.

Clinical Education Alliance Content

The Clinical Education Alliance Sites incorporate information, including modules, capsules, journal articles, medical news, references, interactive case studies, other continuing education material, downloadable software applications, advertising, and other healthcare information, which is intended for adults who are licensed healthcare professionals. This information is not intended to serve as a substitute for the healthcare professional’s clinical judgment. If you are a consumer who chooses to read this professional-level information on Clinical Education Alliance Sites, you should not use or rely on that information as professional medical advice or use it to replace any relationship with your physician or other qualified healthcare professional or any information they may have provided to you. For medical issues or concerns, including decisions about medications and other treatments, consumers should always consult their physician or, in serious cases, seek immediate assistance from emergency personnel.

The Content on the Clinical Education Alliance Sites is developed or selected in accordance with our published Editorial Policies. However, users access and use this material at their own risk. It is the reader’s job to evaluate the accuracy of any information and results from interactive programs found on the Clinical Education Alliance Site. If you are a healthcare professional, you should rely on your professional judgment in evaluating any and all information and confirm the information contained on the Clinical Education Alliance Sites with other sources and reliable third parties before basing any treatment or advice on it. If you are a consumer, you should evaluate the information together with your physician or another qualified healthcare professional.

DISCLAIMERS AND LIMITATIONS OF LIABILITY

THE CONTENT, APPLICATIONS, SOFTWARE, AND ALL OTHER MATERIAL ON THE CLINICAL EDUCATION ALLIANCE SITES ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT. ALL WARRANTIES, EXPRESS OR IMPLIED, ARE HEREBY DISCLAIMED. CLINICAL EDUCATION ALLIANCE SHALL NOT BE LIABLE FOR ANY SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, INCLUDING, WITHOUT LIMITATION, PHYSICAL HARM OR INJURIES, LOST REVENUES, OR LOST PROFITS, RESULTING FROM THE USE OR MISUSE OF THE CLINICAL EDUCATION ALLIANCE SITES, OR ANY INFORMATION, APPLICATIONS, MATERIALS, OR SOFTWARE THEREON, EVEN IF CLINICAL EDUCATION ALLIANCE HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, OR FOR ANY CLAIM BY ANOTHER PARTY. CLINICAL EDUCATION ALLIANCE DOES NOT WARRANT THAT THIS SITE OR ANY APPLICATIONS OR SOFTWARE WILL BE FREE OF BUGS, INACCURACIES, OR ERRORS, NOR DOES CLINICAL EDUCATION ALLIANCE WARRANT THAT ANY SITE, SOFTWARE, OR APPLICATION IS FREE OF VIRUSES OR OTHER HARMFUL ELEMENTS.

A user’s use of the Clinical Education Alliance Sites, and any reliance on any materials, information, software, or applications, is at the user’s own risk. You agree that you hereby release Clinical Education Alliance and its affiliates, owners, respective directors, officers, employees, advertisers, authors, and contributors from any and all liability or obligations arising from the use of the Clinical Education Alliance Sites. A user’s sole remedy for any problem or concern is to exit the Web site or application. You agree that you will indemnify and hold Clinical Education Alliance harmless for any loss, damages, or liability suffered by Clinical Education Alliance as a result of your use of any Clinical Education Alliance Site or material, application, information, or software thereon or your submission of any material to Clinical Education Alliance. Clinical Education Alliance reserves the right to restrict or limit access to this Web site.

CEA Programs, Tools, and Databases

The Clinical Education Alliance Sites include interactive programs, clinical tools, and databases intended for the use of healthcare professionals. These materials are not intended as professional advice or recommendations of particular products. Physicians and other healthcare professionals who use our interactive programs, tools, or databases should exercise their own clinical judgment as to the results. Consumers who use the tools or databases do so at their own risk.

Individuals with any type of medical condition are specifically cautioned to seek professional medical advice before beginning any sort of health treatment. For medical concerns or issues, including decisions about medications and other treatments, users should always consult their physician or other qualified healthcare professional.

Ownership of Clinical Education Alliance Sites—Copyright and Trademarks

The entire contents and design of the Clinical Education Alliance Sites, including the software applications, tools, and databases, are protected under US and international copyright laws. These materials are owned by CEA or its affiliates or are used with permission of their owners or as otherwise authorized by law. All rights are reserved, worldwide. You may look at the Clinical Education Alliance Sites, download individual articles or applications to your personal computer or handheld device, and print a reasonable number of pages for your own personal reference. You must not remove any copyright notices from our materials. We reserve all our other rights. This means you may not sell, rewrite, or modify any content or other material found on any Clinical Education Alliance Site, redistribute it, put it on your own Web site, or use it for any commercial purpose without our prior written authorization.

The names of the CEA products and services are protected by trademark laws in the United States. Any use of our trademarks or service marks requires prior written approval from CEA.

You may link to a CEA Web site if your Web site offers products, services, or information of interest to the professional healthcare community. You are not allowed to link to the Clinical Education Alliance Sites if you post illegal, obscene, or offensive content or if the link is likely to have a negative impact on CEA’s reputation. Any other use, such as framing any part of a CEA Web site or incorporating any CEA content into another Web site, product, or application, requires advance written permission from Clinical Education Alliance. Clinical Education Alliance assumes no responsibility for any Web sites or materials that are linked to Clinical Education Alliance Sites or materials.

Software Products and Applications

Clinical Education Alliance makes some software and accompanying documentation available for downloading from our Web sites and/or from iTunes. These materials are protected by copyrights under US and international law and are owned by Clinical Education Alliance or companies that have licensed the software to us. We do not transfer any ownership rights in software or documentation to you when you download it from our Web site and/or directly from iTunes. You may use the software and accompanying documentation for their intended purpose. You are not authorized to further copy or distribute the software and accompanying documentation, nor may you attempt to recreate or reverse engineer our software or applications. In addition, some software available for downloading from our Web sites and/or from iTunes is subject to US export controls. By downloading or using such software, you are representing to us that your download of such software complies with these controls.

US Government End Users

If you are affiliated with the US government, please note that the software and documentation available on our Web sites and/or directly from iTunes are “commercial items,” as that term is defined in 48 C.F.R. 2.101 (October 1995), consisting of “commercial computer software” and “commercial computer software documentation,” as such terms are used in 48 C.F.R. 12.212 (September 1995). Consistent with 48 C.F.R. 12.212 and 48 C.F.R. 227.7202-1 through 227.7202-4 (June 1995), all US government end users acquire the software and documentation with only those rights set forth herein.

Social Media, Message Boards, and Forums

Clinical Education Alliance offers users the opportunity to engage in social media interactions with both experts and other users of the sites. As with other online social media, users must exercise sound judgment in both the information that they post and in how they assess the postings of other users. As such, users are expected to adhere to the social media recommendations made by the American Medical Association when utilizing the social media capabilities of CEA sites. In particular, users must be cognizant of standards of patient privacy and confidentiality that must be maintained in all environments and must not post identifiable patient information on CEA sites. In social media interactions, users must maintain appropriate boundaries of the patient–physician/care provider relationship in accordance with professional ethical guidelines just as they would in any other context. Users acknowledge that privacy settings are not absolute and that once on the Internet, content posted by them may be copied by third parties and republished out of the control of Clinical Education Alliance. Thus, users should routinely monitor their own Internet presence to ensure that the personal information and content that they post and, to the extent possible, that is posted about them by others is accurate and appropriate.

Users are expected to refrain from submitting comments or messages that are defamatory, hateful, or obscene or that harass others. Users may not impersonate any other person or violate any other person’s or entity’s legal rights or submit falsified credentials or experiences. Users agree that they will not submit any materials that violate or infringe any copyrights, trademarks, patents, trade secret, or other intellectual property rights of any third party. Clinical Education Alliance retains all copyrights in the content posted by users to its sites. Clinical Education Alliance may adopt additional rules to govern use of social media, message boards or forums, to which users will be subject.

Copyright and Other Legal Violations

If you believe that any material on this Web site infringes your copyright, please notify us as follows, under the Digital Millennium Copyright Act (“DMCA”). To notify us, the DMCA requires that you: 1. Send an email notice to Clinical Education Alliance at customersupport@clinicaloptions.com. 2. Include the following information in your email: a. Identify the copyrighted work(s) you claim is infringed; b. Identify the material you claim is infringing the copyright(s) and give enough information for Clinical Education Alliance to locate that material; c. Include a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf (the “Claimant”); d. Include the Claimant’s name, address, and telephone number(s); e. Include a statement that the Claimant has a good faith belief that use of the disputed material is not authorized by the copyright owner or his agent; and f. Include a statement, under penalty of perjury, that the information in the notification of copyright infringement is accurate and that the Claimant is the copyright owner or is authorized to act on behalf of the copyright owner.

If you believe any content or material on the Clinical Education Alliance Sites violates any laws, please notify customersupport@clinicaloptions.com. Please include details about your concerns and an email address for contacting you.

Governing Law

Clinical Education Alliance controls the Clinical Education Alliance Sites from its offices in the state of Virginia in the United States of America. The Clinical Education Alliance Sites can be accessed from any of the United States and from other countries worldwide. Since the laws of each state or country may differ, both you and Clinical Education Alliance agree that the laws of Virginia, without regard to conflicts of laws principles, will apply to all matters relating to use of the Clinical Education Alliance Sites and materials, including software and applications.

Clinical Education Alliance makes no representation that materials on these sites are appropriate or available for use in countries aside from the United States. Accessing the Clinical Education Alliance Sites from territories where their contents are illegal is prohibited. Those who choose to access these sites from other locations do so at their own risk and are responsible for compliance with any and all applicable local laws or regulations.

Acceptance Procedure

By downloading or accessing materials on the Clinical Education Alliance Sites and/or directly from iTunes or registering with us, you agree to all the terms and conditions in this agreement, including the Terms of Use and Privacy Policy. If you disagree with any of these Terms of Use or Privacy Policy, please refrain from using the Clinical Education Alliance Sites or materials.

Privacy Policy

Because we provide education for healthcare professionals, we pay special attention to privacy issues. The purpose of our Privacy Policy is to identify the information we may collect about you, describe the uses we may make of your information and the security measures we take to protect it, and discuss your options for controlling your information. You can review our Privacy Policy by clicking on the “Privacy Policy” link at the bottom of designated pages on the Clinical Education Alliance Sites.

Disputes

If you fail to comply with these terms, we have the right to suspend or eliminate your account and remove any information you have placed on our site, including your registration information. We may also take any legal action we think is appropriate. If there is any dispute between us concerning this agreement or your use of any Clinical Education Alliance Site or materials or applications, we both agree to submit the dispute to nonbinding mediation, followed by binding arbitration. Both the mediation and the arbitration will be governed under the rules of the American Arbitration Association, and the venue for the arbitration will be Virginia.

Questions or Concerns About Our Terms of Use

For questions or concerns about these Terms of Use, please send an email to customersupport@clinicaloptions.com

These terms of use were last updated in July 2021.